LARANJEIRA CHARLES ANTHONY
Known title: Chief Technical OfficerCIK: 0001524338
Associated companies
Transaction History
| PCRX | ▲ Buy | Option Exercise | 6,000 | $230K | 6/14/2022 | View on chart |
| PCRX | ▲ Buy | Grant | 9,900 | $0 | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,521 | $149K | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,633 | $98K | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 516 | $31K | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 267 | $17K | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,813 | $173K | 6/6/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 7,500 | $331K | 11/22/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.